ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) saw a significant decrease in short interest in September. As of September 15th, there was short interest totalling 2,220,000 shares, a decrease of 8.3% from the August 31st total of 2,420,000 shares. Based on an average trading volume of 348,000 shares, the days-to-cover ratio is currently 6.4 days.

ANI Pharmaceuticals Trading Up 1.5 %

Shares of NASDAQ:ANIP opened at $59.66 on Tuesday. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of 37.29 and a beta of 0.71. The business’s 50 day moving average price is $60.60 and its 200-day moving average price is $63.36. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter in the previous year, the company posted $1.06 EPS. The company’s revenue was up 18.5% compared to the same quarter last year. On average, equities research analysts forecast that ANI Pharmaceuticals will post 3.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Raymond James lifted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Truist Financial reiterated a “hold” rating and issued a $60.00 target price (down previously from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. Finally, StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $78.80.

Insider Activity at ANI Pharmaceuticals

In other news, COO Muthusamy Shanmugam sold 14,257 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total value of $900,472.12. Following the sale, the chief operating officer now directly owns 635,363 shares of the company’s stock, valued at $40,129,527.08. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 26,007 shares of company stock worth $1,642,990 over the last quarter. 12.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Dimensional Fund Advisors LP boosted its stake in ANI Pharmaceuticals by 6.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock worth $32,628,000 after purchasing an additional 33,359 shares during the period. Rubric Capital Management LP lifted its position in shares of ANI Pharmaceuticals by 32.8% during the 4th quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after acquiring an additional 277,989 shares during the period. CastleKnight Management LP purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $513,000. Ranger Investment Management L.P. grew its holdings in shares of ANI Pharmaceuticals by 1.8% in the 4th quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock worth $23,965,000 after acquiring an additional 7,769 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter worth $132,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.